CAMBRIDGE, England--(BUSINESS WIRE)--Mission Therapeutics, a drug discovery and development company focused
on selectively targeting deubiquitylating enzymes (DUBs) to treat
cancer, neurodegenerative and other diseases, announced the appointment
of Dr Anne Phelan as Senior Vice President, Head of Discovery Research,
effective 20 March 2017.

Dr Phelan has spent over 20 years in the pharmaceutical industry and
brings with her a wealth of drug discovery experience across a number of
therapy areas as well as operational knowledge. She joins Mission from
BenevolentAI (formerly Stratified Medical), where she served as VP, Drug
Discovery. Previously, she held a number of senior positions within
Pfizer including COO and Head of Pharmacology at Pfizer Neusentis in
Cambridge UK.

Dr Phelan obtained her undergraduate and doctoral degrees in Genetics
from the University of Liverpool, and carried out her post-doctoral
training at the MRC Institute of Virology in Glasgow.

“Anne’s appointment further reinforces our scientific expertise and
operational capabilities as we consolidate our DUB discovery platform
and focus on identifying novel disease targets and producing next
generation compounds. She will play an invaluable role as we continue to
build our internal pipeline and prioritise novel therapeutic programmes
for pre-clinical and clinical development. We are pleased to welcome
Anne to our leadership team.”

Dr Anne Phelan newly appointed SVP, Head of Discovery Research, added:
“Mission has rapidly earned a reputation as a leading biotech in the
Cambridge, UK area. The Company’s science and unique DUB platform, with
applicability across numerous therapeutic areas, is impressive and has
significant commercial potential. I am looking forward to working
alongside Mission’s highly experienced and ambitious leadership team to
advance its programmes beyond the discovery phase.”

ENDS

NOTES TO EDITORS:

About MissionTherapeutics

Mission Therapeutics, an early-stage drug development company targeting
the ubiquitin pathway for the treatment of cancer, neurodegenerative,
and other diseases of unmet need. The Company has built a leading
platform for the discovery and development of first-in-class,
small-molecule drugs that selectively target deubiquitylating enzymes
(DUBs) – an emerging drug class that is attracting significant
commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers,
including Cancer Research UK Laboratories and the University of
Cambridge's Jackson Laboratories at the Gurdon Institute, and a
leadership team that has broad international, commercial and scientific
experience.

In February 2016, the Company completed an $86m financing that was led
by Imperial Innovations and Woodford Patient Capital Trust and included
participation from existing investors Sofinnova Partners, Roche Venture
Fund, Pfizer Venture Investments and SR One.

Mission Therapeutics was founded in 2011 and is based at the Babraham
Research Campus, Cambridge, UK.